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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S136tacrolimus. The CliniMACS (IND 14359) collects HPC, Apher-
esis- CD34-enriched cells; target dose of 10.0 x 106 CD34+
cells/kg with 2.0 x 105 CD3+ T cells/kg added back.
Two patients have received AlloSCTs to date. Pt. 1 is a 10yr _
with a history of abnormal Transcranial Dopplers andmultiple
VasoocclusiveCrises. Pt. 2 isa13yr\with twopreviousstrokes,
hypertransfusion and Moyamoya. Both utilized maternal do-
nors without complications, and had early myeloid engraft-
ment, 92% whole blood and  85%RBC donor chimerism, no
aGVHDor cGVHD, and are alivewithNED (Figure 2). Twomore
patients are undergoing conditioning.
Early results indicate FHI TCD AlloSCT is feasible in high-risk
SCD patients who lackMSD or URD. A larger cohort is needed
to assess long-term safety and outcomes (Supported by FDA
5R01FD004090-02 and a grant from Otsuka) (IND #14359
and NCT 01461837).187
Automated Production of Clinical-Grade CMV-Speciﬁc T
Cells to Implement Immunotherapy at the Bedside
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MD Anderson Cancer Center, Houston, TXDespite curative potential of hematopoietic stem-cell trans-
plantation (HSCT) signiﬁcant morbidity, mortality, and
ﬁnancial cost secondary to opportunistic infections remains.
Immune reconstitution prevents and treats infections. Select
academic facilities and biomedical companies infuse donor-
derived T cells selectively cultured on antigen, identiﬁed
based on desired T-cell receptor expression, or selected for
ability to generate gamma-interferon (g-IFN) . The “capture”
of T cells secreting g-IFN in response to stimulation with
antigen is rapid (T cells are available within hours of collec-
tion from donor) and independent of human leukocyte an-
tigen. The limitation of capturing these desired T cells using a
magnetic bi-speciﬁc reagent (that recognizes CD45 and g-
IFN) is the cumbersome and labor-intensive procedure
associated with using ﬁrst-generation CliniMACS device
from Miltenyi Biotec. We report the ﬁrst experience using
second generation CliniMACS Prodigy device to automate
production of T cells captured for their ability to generate g-
IFN in response to cytomegalovirus (CMV). Eight steady-state
apheresis products from CMV seropositive donors were
processed. Following activationwith PepTivator CMV pp65, T
cells secreting g-IFN were isolated in a closed, hands-free
system within 12 hours. Two donors failed to produce CMV-
speciﬁc T cells due to low starting number of CD3+g-IFN+ T
cells (<0.01%). There was an average of 0.07% g-IFN CD4+ T
cells (range 0.03-0.61%) prior to capture and an average of
62.2% (range 14.7-91.4%) after enrichment. The g-IFN CD8+ T
cells prior to enrichment was 0.43% (range 0.07-0.56%) and
89.36% (range 61.6-94.2%) after capture. This yielded an
average of 3x105 CD3+g-IFN+ Tcells. For a 70 kg adult and a 30
Table 1
IFN-g+CD4+ T cells
among viable CD4+ T
lymphocytes (n¼6)
IFN-g+CD8+ T cells
among viable CD8+ T
lymphocytes (n¼6)
Pre-enrichment (%) 0.07 (0.03 e 0.61) 0.43 (0.07 e 0.56)
Post-enrichment (%) 62.20 (14.73 e 91.39) 89.36 (61.59 e 94.20)
Mean Yield / 109
starting TNCs
1.5x105 1.5x105
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S137kg child this yields 4x103 and 104 cells/kg, respectively, of
pathogen-speciﬁc T cells, which is consistent with the
numbers needed to treat chemotherapy-refractory CMV in
clinical trials using the ﬁrst generation technology. We are
implementing a pre-screening approach to identify CMV
seropositive donors that may fail to collect and extending our
evaluation of the Prodigy system to capture pathogen-spe-
ciﬁc T cells with speciﬁcity other than CMV. These data
demonstrate automated production of CMV-speciﬁc T cells is
feasible and will enable investigators to produce clinical-
grade pathogen speciﬁc allogeneic T cells for add-back after
HSCT at multiple points-of-care broadening the application
of this promising immunotherapy.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES188
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Background: The safety and efﬁcacy of UCB as a donor
source for hematopoietic stem cell (HSC) transplantation is
well established (Wagner/Cairo et al, Blood, 1996; Kurtzberg
et al, NEJM,1996). Further, the naiveté of these cells allows for
greater HLA mismatch and leads to decreased rates of
chronic GVHD (Liao/Cairo et al, Exp Hem,2011). However, the
number of HSC’s in each UCB unit is signiﬁcantly less than
that obtained from peripheral blood and bone marrow
(Cairo/Kurtzberg et al, Transfusion, 2005), prolonging time to
engraftment (Cairo et al, Blood,1997). With longer periods of
neutropenia increasing the risk of infectious complications in
UCB transplantation, much effort has been made to improve
time to engraftment in UCB transplants. One strategy
developed by Cellgene Cellular Therapeutics (CCT) is co-
infusion of UCB with HPDSC’s. HPDSC’s, derived from CCT’s
proprietary process, represent a more immature HSC source,
containing a higher concentration of CD34+ cells as well as
CD34+/CD45- cells than UCB. Augmenting the graft with
early progenitors may increase the engraftment potential of
UCB. Studies using a NOD/SCID mouse model demonstrate
earlier engraftment when HPDSC’s are combined with UCB
transplant and increased engraftment compared to UCB or
HPDSC’s alone.
Objective: To determine the feasibility and safety of com-
bined UCB transplantationwith HPDSC’s usingmyeloablative
or reduced intensity conditioning for malignant and non-
malignant diseases.
Methods: We have developed a multicenter consortium
(CCT-HPDSC-UCBT-PI-001) to investigate this approach
(Figure1A). Patients with eligible malignant and non-malig-
nant diseases who have a single or double UCB donor (4/6-6/and CBT clinical trial and (B) the overall treatment plan.
